|This Slide: #94 of 100|
Slide #94. AstraZeneca — Omthera
Omthera Pharmaceuticals and AstraZeneca announced today that the companies entered into a merger agreement under which AstraZeneca will acquire all of the outstanding stock of Omthera for an upfront payment of $12.70 in cash per share, approximately $323 million aggregate value ($260 million after subtracting cash), plus a contingent value right for up to $4.70 per share, equaling approximately $120 million and for a total value of up to $443 million. Covington & Burling LLP advised Omthera on the transaction.
AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business. Co. focuses on three main therapy areas: oncology - aims to change the practice of medicine and transform the lives of patients living with cancer; cardiovascular, renal & metabolism includes treatment of four interrelated conditions - cardiovascular disease, heart failure, metabolic and renal diseases; and respiratory and immunology - aims to transform the treatment of asthma and COPD by eliminating preventable asthma attacks across disease severities and removing COPD as a cause of death through earlier, biology-led treatment.
Open the AZN Page at The Online Investor »
Free AZN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (3.71 out of 4)